Regenerative Medicine in Las Vegas
Regenerative medicine aims to help the body repair its own damaged tissue rather than only managing its symptoms. Our evidence-graded protocols use the signaling peptides BPC-157, TB-500, and GHK-Cu - prescribed and monitored by board-certified neurologist Dr. Charles Kamen, MD. Labs first, individualized protocols, and peptides from licensed US pharmacies. Start with an $88 evaluation.
LiveNow Longevity ·
Evaluate the product, not the category
The term regenerative medicine is used for cellular products, exosomes and other approaches studied for tissue repair. They are not a single treatment with a shared safety record. Ask what the product contains, how it is given, which condition is being treated and what human evidence supports that use.
A medical assessment begins with the health concern and current care. Depending on the concern, appropriate next steps may include standard treatment, rehabilitation, further diagnostic assessment or specialist referral. Research interest does not make an investigational product a necessary part of care.
Stem cells and exosomes
Some exact cellular therapies are approved for specific diseases. Ryoncil’s approval for pediatric steroid-refractory acute graft-versus-host disease is one example. It is not an approval of placental IV infusions for recovery or longevity. FDA’s exosome alert reports no approved exosome products.
This page does not offer stem-cell or exosome infusions. Consent and physician supervision cannot substitute for the applicable product-specific federal pathway. A trial registration or commercial supplier certificate is not a marketing authorization.
What about BPC-157, TB-500 and GHK-Cu?
These names appear in tissue-repair research and commercial marketing, but preclinical findings do not establish that a proposed injection will heal a person’s tendon, ligament, skin or joint. A full-length peptide and a marketed fragment should not be treated as the same product.
FDA’s current compounding safety tables discuss potential risks and limited safety information for several peptides, including BPC-157, TB-500 and injectable GHK-Cu. The table separates active Category 2 entries from withdrawn nominations. Removal of a nomination, committee discussion or pharmacy registration is not FDA approval of a finished drug. No availability of those protocols is promised here.
Questions for a medical assessment
Bring a description of symptoms, existing diagnoses, current medications and relevant prior results. The clinician determines whether an examination, testing or referral is needed; no blanket laboratory panel or treatment outcome is promised.
Ask about the evidence for your actual condition, reasonable alternatives, material risks, expected monitoring and full costs. A general evaluation is separate from any treatment decision. This guide supplies no investigational-treatment price or prescription guarantee.
Common Questions
Are regenerative treatments generally safe?
There is no single safety answer for the category. Product, route, indication and evidence matter. FDA has reported serious harms associated with unapproved regenerative products; monitoring does not remove every risk.
Do animal tissue-repair studies show that peptides work for patients?
No. Animal or mechanistic findings may justify further research, but do not establish human effectiveness, dosing, safety or legal availability.
Will an assessment lead to a regenerative prescription?
No prescription or regenerative protocol is promised. Medical assessment may lead to standard care, further testing, a referral or no additional treatment.
Does physician supervision or informed consent establish legal access?
No. Consent, physician supervision, a supplier certificate or state permission does not establish that a particular product may be marketed under federal law. The exact product, intended use and applicable regulatory pathway matter.
What should I ask before paying for a proposed treatment?
Ask for the exact product and manufacturer, the proposed route and use, its FDA approval or applicable investigational authorization, the human evidence, material risks, alternatives and a written itemized cost estimate. Trial registration alone is not FDA approval.
General educational information. An individual medical assessment and the exact product’s regulatory status are separate from this guide.